These results indicate that in Ipi-P patients, Tumor Infiltrating Lymphocytes (TILs) are already preselected by the tumor antigenic landscape during prior IO treatment, and resistance may arise from T-cell exhaustion through PD-1/PD-L1 signaling. This evidence concerns the gene CD274 and neoplasm.